fexofenadine hydrochloride - Profile

What are the generic drug sources for fexofenadine hydrochloride and what is the scope of freedom to operate?

Fexofenadine hydrochloride is the generic ingredient in thirteen branded drugs marketed by Chattem Sanofi, Barr, P And L, Taro, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Hetero Labs Ltd V, Rising, Sun Pharm Inds, Teva, Wockhardt, Contract Pharmacal, L Perrigo Co, Granules, Sciegen Pharms, Unique, Aurobindo Pharma, Dr Reddys, Impax Pharms, and Sun Pharm, and is included in thirty-five NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fexofenadine hydrochloride has forty-three patent family members in thirty-eight countries.

There are six tentative approvals for this compound.

Summary for fexofenadine hydrochloride

International Patents:	43
US Patents:	1
Tradenames:	13
Applicants:	20
NDAs:	35

Generic filers with tentative approvals for FEXOFENADINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		60MG;120MG	TABLET, EXTENDED RELEASE;ORAL
		60/120MG	TABLET, EXTENDED RELEASE; ORAL
		180MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for FEXOFENADINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CHILDREN'S ALLEGRA HIVES	Oral Suspension (OTC)	fexofenadine hydrochloride	30 mg/5 mL	201373	1	2010-01-25

US Patents and Regulatory Information for fexofenadine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	ALLEGRA	fexofenadine hydrochloride	CAPSULE;ORAL	020625-001	Jul 25, 1996		DISCN	No	No
Barr	FEXOFENADINE HYDROCHLORIDE	fexofenadine hydrochloride	CAPSULE;ORAL	076169-001	Jul 13, 2005		DISCN	No	No
Chattem Sanofi	ALLEGRA	fexofenadine hydrochloride	SUSPENSION;ORAL	021963-001	Oct 16, 2006		DISCN	Yes	No
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	SUSPENSION;ORAL	201373-001	Jan 24, 2011		OTC	Yes	Yes	8,933,097		Y

Expired US Patents for fexofenadine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	CHILDREN'S ALLEGRA HIVES	fexofenadine hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021909-003	Jan 24, 2011	5,578,610
Chattem Sanofi	ALLEGRA ALLERGY	fexofenadine hydrochloride	TABLET;ORAL	020872-007	Jan 24, 2011	5,855,912*PED
Chattem Sanofi	ALLEGRA	fexofenadine hydrochloride	CAPSULE;ORAL	020625-001	Jul 25, 1996	6,187,791*PED
Chattem Sanofi	CHILDREN'S ALLEGRA HIVES	fexofenadine hydrochloride	SUSPENSION;ORAL	201373-002	Jan 24, 2011	6,187,791*PED

International Patents for fexofenadine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Israel	192067
South Africa	200803985
Slovenia	1965768
Brazil	PI0619895

Investment and Fundamentals Analysis of Fexofenadine Hydrochloride

Last updated: February 20, 2026

What is Fexofenadine Hydrochloride?

Fexofenadine hydrochloride is an antihistamine used to treat allergic rhinitis (hay fever) and chronic idiopathic urticaria. It blocks peripheral H1 receptors without significant sedative effects. Marketed under brands like Allegra, it is a non-sedating, second-generation antihistamine.

Market Overview and Commercial Potential

The global antihistamine market was valued at approximately USD 4.3 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 6% through 2028. Fexofenadine holds a significant market share within this segment. Its advantages over first-generation antihistamines (less sedation, longer duration) sustain demand.

Major pharmaceutical players (e.g., Sanofi, Teva) produce formulations with patent expirations generally in the 2010s or early 2020s, opening generic opportunities.

Key Drivers

• Rise in allergic conditions: Increased urbanization and pollution escalate allergic rhinitis prevalence.
• Aging populations: Older demographics have higher allergy treatment needs.
• Generic market growth: Post-patent expiration, generic versions increased accessibility and price competition.

Competitive Landscape

Company	Product Name	Patent Status	Market Share (Approximate)
Sanofi-Aventis	Allegra	Expired	40%
Teva Pharmaceuticals	Fexofenadine	No patent	30%
Others	Various	Expired	30%

Market entry of generics has led to price reductions, affecting margin potential for branded formulations.

R&D and Regulatory Considerations

Fexofenadine's patent expirations reduce R&D exclusivity value but open manufacturing and formulation opportunities. Regulatory approvals are mostly streamlined, with FDA ANDA (Abbreviated New Drug Application) pathways now dominant. Cost of compliance remains stable, but market access depends on regional regulatory stringency.

Investment Outlook

• Short-term: Limited R&D returns as patent expiration limits exclusivity; revenue from ongoing sales and generics.
• Mid to Long-term: Opportunities in formulation innovation, combination therapies, and new indications. Biosimilars are not relevant here, but digital health integration may open potential in adherence management.
• Risks: Patent litigation, generic price erosion, regulatory hurdles in different regions, and market saturation.

Financial Fundamentals

While specific company or product-level financials vary, the overall antihistamine segment projects stable revenues. Generic sales margins are lower but compensate with higher volume.

• Gross margins for branded formulations range from 60% to 70%.
• For generics, margins can be 40% to 55%, subject to price erosion.
• R&D expenditure for new antihistamines averages USD 100 million to 200 million per project, but reentry into novel indications could increase the cost structure.

Strategic Considerations

Potential to license formulations, pursue OTC status in specific markets, or develop combination therapies with other antihistamines or nasal steroid products.

The patent expiry landscape suggests focusing on formulation differentiation, delivery methods, or digital engagement strategies to sustain market share.

Key Takeaways

• Fexofenadine hydrochloride has a mature, highly competitive market with declining patent protections.
• Growth prospects hinge on market expansion, formulations, and new indications.
• R&D investment is limited but potentially valuable for innovation or combination therapies.
• Regional regulatory and market dynamics heavily influence profitability.
• For investors, exposure via companies with diversified portfolios in allergy treatments offers stable risks and returns.

FAQs

1. What are the major patent expiration dates for Fexofenadine?
Most patents expired by the late 2010s or early 2020s, enabling generic competition.

2. Are there any significant ongoing R&D programs for new indications?
No major publicly disclosed R&D programs target novel indications for fexofenadine; focus remains on formulation improvements and combination products.

3. How do generic versions impact profitability?
They significantly reduce prices and margins but increase volume sales. Companies rely on cost-efficiency and distribution strategies to maintain profitability.

4. What regulatory hurdles exist for market expansion?
Regional variations in approval processes, bioequivalence requirements, and marketing restrictions can delay or limit access.

5. What are alternative growth strategies for suppliers?
Formulation innovation, digital adherence tools, OTC approvals, and combination therapies present viable options for extending product lifecycle.

---

References

1. MarketsandMarkets. (2021). Allergic Rhinitis Market by Product, Route of Administration, Distribution Channel, and Region - Global Forecast to 2028.
2. U.S. Food and Drug Administration. (2022). ANDA filings and patent information.
3. Allied Market Research. (2020). Antihistamines Market Overview.
4. Pharma Intelligence. (2022). Patent expiry timelines for antihistamines.
5. Statista. (2022). Global market share of antihistamine products.